The correct risk categorization and staging of upper tract urothelial cancer (UTUC) is key for disease management. Computed tomography urography (CTU) and urinary cytology have limited accuracy for risk stratification of UTUC. Ureteroscopy may increase the risk of bladder recurrence. Recently, Bladder EpiCheck^TM (EpiCheck) showed a high accuracy in the detection of bladder cancer. The aim of the study is to investigate the diagnostic accuracy of EpiCheck in the clinical management of UTUC and to compare it with urinary cytology.

中文翻译：

---

DNA 甲基化尿液生物标志物检测在上尿路上皮癌诊断中的作用：来自单中心前瞻性临床试验的结果。

上尿路上皮癌 (UTUC) 的正确风险分类和分期是疾病管理的关键。计算机断层扫描尿路造影 (CTU) 和尿细胞学检查对 UTUC 风险分层的准确性有限。输尿管镜检查可能会增加膀胱复发的风险。最近，Bladder EpiCheck ^TM (EpiCheck) 在膀胱癌的检测中显示出很高的准确性。本研究的目的是调查 EpiCheck 在 UTUC 临床管理中的诊断准确性，并将其与尿细胞学进行比较。